7MM B-cell non-Hodgkin’s lymphoma cases to reach 230,000 in 2033

Five diagnosed prevalent cases will grow to over 714,000.

Diagnosed incident cases of B-cell non-Hodgkin’s lymphoma (B-cell NHL) across the seven major markets (7MM) are expected to increase from 200,844 in 2023 to nearly 230,000 by 2033 at an annual growth rate (AGR) of 1.44%, said GlobalData.

In addition, five-year diagnosed prevalent cases will grow from almost 634,000 to over 714,000 at an AGR of 1.26%.

Whilst early detection and developments in therapeutics have improved the prognosis for many patients, the varied clinical courses of B-cell NHL pose significant management challenges, particularly for rarer subtypes such as mantle cell lymphoma.

“B-cell NHL remains a complex spectrum of malignant neoplasms, each of which exhibits idiosyncratic clinical manifestations and behaviours,” said Zachary Natale, MPH, Senior Epidemiologist at GlobalData.

“It is imperative for healthcare workers, public health professionals, and researchers to develop a more nuanced understanding of B-cell NHL’s subtypes to best address them as respective diseases,” Natale added.

*7MM = US, France, Germany, Italy, Spain, UK, and Japan.